Navigation Links
Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
Date:4/8/2013

RIDGEFIELD, Conn., April 8, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced that data from its pivotal STARTVerso™ 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress™ 2013: 48th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place from April 24-28 in Amsterdam, The Netherlands.

The STARTVerso™ 1 trial evaluated faldaprevir (BI 201335), an investigational oral protease inhibitor specifically designed to target and inhibit viral replication in the liver, in combination with pegylated interferon and ribavirin (PegIFN/RBV). The study was conducted in treatment-naïve patients with genotype-1 infection, the most common and one of the most challenging types of hepatitis C to cure.

Further sub-analyses from Boehringer Ingelheim's interferon-free Phase 2b SOUND-C2 study will also be presented at the Congress. The SOUND-C2 trial evaluated the interferon-free combination of faldaprevir and BI 207127, an investigational non-nucleoside NS5B polymerase inhibitor, plus ribavirin.

Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. Through robust science, Boehringer Ingelheim's goal is to find answers to the ongoing challenges faced by a diverse population of patients with hepatitis C.

The STARTVerso™ 1 abstract can be accessed through the Congress website beginning on April 23 and the SOUND-C2 abstracts can be accessed today. Oral PresentationStudyLead AuthorPresentation DetailsSTARTVerso™ 1

P. Ferenci

Embargoed until April 23 at 12:00PM CET (6:00AM ET)Poster Presentations'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
3. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
4. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
5. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
6. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
7. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
8. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
9. Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
(Date:7/25/2014)... According to a new market ... Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and ... and Forecast (Value and Volume), 2013 - 2019", the ... in 2012 and is expected to grow at a ... USD 32.24 billion in 2019. Browse the ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... the "Global Ophthalmic Diagnostic Devices Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 About Ophthalmic Diagnostic Device ... device used to identify a defect or deficiency in ... patients with ophthalmic disorders such as presbyopia, cataracts, glaucoma, ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... Simpson Eldredge Hersh & Jardine, P.C., one of the nations, ... lawsuit in Ohio against DePuy Orthopaedics, Inc. on behalf of ... ASR XL Acetabular System hip replacement. On August ... Johnson (NYSE: JNJ ), announced a voluntary recall ...
... Sept. 28 Cobalis Corp. (Pink Sheets: ... Call to provide investors and shareholders with further details and ... and legal issues. Shareholders and investors MUST RSVP ... October 5, 2010 at 1:15pm Pacific Time. Interested parties may ...
Cached Medicine Technology:Class Action Lawsuit Filed Against DePuy Orthopaedics, Inc. 2Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010 2
(Date:7/28/2014)... New York (PRWEB) July 28, 2014 According ... Mark Caller, principal owner of The Marcal Group ... Harel Media Group (HMG). A contract, as well a broad ... Medical Center’s website, as well as branding services and marketing. ... the work completed by HMG throughout the course of the ...
(Date:7/28/2014)... 28, 2014 TherapySites, the ... professionals, announced today its affiliation with the Illinois ... new relationship allows TherapySites to continue to extend their ... and promotional offers. , “There has been a fundamental ... With nearly 3 billion Internet users, it is ...
(Date:7/28/2014)... According to the Heartburn No More PDF review ... will help people get rid of acid reflux ... about heartburn and acid reflux. In addition, inside this book, ... risk factors for reflux disease. , Vkool informs in ... of symptoms of reflux disease naturally without medications. The book ...
(Date:7/28/2014)... 2014 Shore Points Capital announced today ... in Loftware, Inc., through a recapitalization of the Company ... the lead investor in Loftware for over nine years, ... leading international provider of enterprise level software solutions for ... great investment for us, and we are proud of ...
(Date:7/27/2014)... Hyaluronic Acid can hold 1,000 times ... to the power of Hyaluronic Serums. , "Hyaluronic acid ... of Sublime Beauty®. "But like collagen, it diminishes with ... improves skin moisture-retention and radiance." , Hyaluronic acid ... healthy and beautiful look. Key Ingredients in the serum ...
Breaking Medicine News(10 mins):Health News:Calko Medical Center Loses Website Twice over Non-Payment, According to Court Documents 2Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Shore Points Capital Announces Sale of Portfolio Company Loftware 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2
... ... is the ability to earn an income. It is this ability ... mortgage but also to plan and save for tomorrow,s college and retirement costs. ... percent of adults age 21 and over have taken measures to protect their ...
... , Gay Men,s Health Crisis Encourages ... , NEW YORK, Dec. 1 Today on World AIDS ... to continue helping diverse groups disproportionately affected by HIV and ... is announcing an innovative, interactive crystal methamphetamine resource, www.MyMethLife.org ...
... , LOS ANGELES, Dec. ... Clementines kicks off its 2009/2010 growing season with a fresh ... Joy Fawcett - an award-winning soccer player, coach and ... mentor moms on the sidelines and online. Combined with league ...
... functional MRI , TUESDAY, Dec. 1 (HealthDay News) ... a new study has found. , "What we have found ... lead exposure. Distinct areas of the brain are affected differently," ... Hospital Medical Center and a professor of radiology, pediatrics and ...
... to treatment worldwide provide reasons for hope , TUESDAY, Dec. ... still far from over, 2009 could prove to be a ... experts say. , In fact, earlier this month a United ... HIV globally has remained unchanged, at about 33 million, for ...
... intolerance (a condition less severe than gestational diabetes) exhibit ... after birth, according to a new study accepted for ... Endocrinology & Metabolism ( JCEM ). ... between gestational glucose intolerance and postpartum risk of metabolic ...
Cached Medicine News:Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 2Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 3Health News:Nation's Oldest AIDS Organization Launches Innovative Tool to Reach New Faces of HIV on World AIDS Day 2Health News:Nation's Oldest AIDS Organization Launches Innovative Tool to Reach New Faces of HIV on World AIDS Day 3Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 2Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 3Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 4Health News:Childhood Lead Exposure Causes Permanent Damage: Study 2Health News:A Good Year in the Fight Against AIDS 2Health News:A Good Year in the Fight Against AIDS 3Health News:A Good Year in the Fight Against AIDS 4Health News:Glucose intolerance in pregnancy associated with postpartum cardiovascular risk 2
For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 10.4 mm....
For use with E5381 600 Circling Band (40 style). 2.2 mm diameter, 28.5 mm long....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: When high buckle is required. Overall length: 11.6 mm....
Asymmetrical concave inner surface to conform to globe. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Medicine Products: